Department of Social Pharmacy, University of Ljubljana, Faculty of Pharmacy, Askerceva cesta 7, 1000, Ljubljana, Slovenia.
Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Zaloska Cesta 7, 1000, Ljubljana, Slovenia.
BMC Endocr Disord. 2021 Jun 25;21(1):127. doi: 10.1186/s12902-021-00798-3.
Several new antidiabetic medicines (GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors) have been approved by the European Medicines Agency since 2006. The aim of this study was to evaluate the uptake of new antidiabetic medicines in European countries over a 10-year period.
The study used IQVIA quarterly value and volume sales data January 2006-December 2016. The market uptake of new antidiabetic medicines together with intensity of prescribing policy for all antidiabetic medicines were estimated for Austria, Croatia, France, Germany, Hungary, Italy, Poland, Slovenia, Spain, Sweden, and the United Kingdom. The following measures were determined: number of available new active substances, median time to first continuous use, volume market share, and annual therapy cost.
All countries had at least one new antidiabetic medicine in continuous use and an increase in intensity of prescribing policy for all antidiabetic medicines was observed. A tenfold difference in median time to first continuous use (3-30 months) was found. The annual therapy cost in 2016 of new antidiabetic medicines ranged from EUR 363 to EUR 769. Among new antidiabetic medicines, the market share of DPP-4 inhibitors was the highest. Countries with a higher volume market share of incretin-based medicines (Spain, France, Austria, and Germany) in 2011 had a lower increase in intensity of prescribing policy. This kind of correlation was not found in the case of SGLT-2 inhibitors.
This study found important differences and variability in the uptake of new antidiabetic medicines in the included countries.
自 2006 年以来，欧洲药品管理局已批准了几种新的抗糖尿病药物（GLP-1 受体激动剂、DPP-4 抑制剂和 SGLT-2 抑制剂）。本研究旨在评估新的抗糖尿病药物在欧洲国家 10 年内的应用情况。
本研究使用了 IQVIA 季度价值和销量数据（2006 年 1 月至 2016 年 12 月）。对奥地利、克罗地亚、法国、德国、匈牙利、意大利、波兰、斯洛文尼亚、西班牙、瑞典和英国的新抗糖尿病药物的市场占有率以及所有抗糖尿病药物的处方政策强度进行了评估。确定了以下措施：可用新活性物质的数量、首次连续使用的中位数时间、体积市场份额和年治疗费用。
所有国家都至少有一种新的抗糖尿病药物在连续使用，所有抗糖尿病药物的处方政策强度都有所增加。首次连续使用的中位数时间差异达十倍（3-30 个月）。2016 年新抗糖尿病药物的年治疗费用从 363 欧元到 769 欧元不等。在新的抗糖尿病药物中，DPP-4 抑制剂的市场份额最高。2011 年，西班牙、法国、奥地利和德国等国家基于肠促胰岛素的药物体积市场份额较高，其处方政策强度的增长幅度较低。但在 SGLT-2 抑制剂的情况下，没有发现这种相关性。
本研究发现，纳入的国家在新的抗糖尿病药物的应用方面存在重要的差异和可变性。
